A study recently published in Aging-US suggests that combining oxytocin with an Alk5 inhibitor rejuvenated extremely old, frail male mice, boosting both strength and lifespan. However, female mice were not so fortunate, only showing short-term improvements, which highlights a major difference in aging biology in how each sex responds to anti-aging therapies.
According to the paper, the drug combo restored youthful protein patterns in blood and targeted key pathways that drive tissue decline; and because the drugs are already clinically accessible, the approach could move towards human testing, opening a new direction in longevity research.
“These findings establish the significant health-span extension capacity of OT+A5i and emphasize the differences in aging and in response to longevity therapeutics between the sexes,” said first author Cameron Kato, who led the research, along with corresponding author and Aging-US Editorial Board Member Irina M. Conboy at the University of California, Berkeley.
How the Drug Combo Worked
The researchers designed a two-part treatment to address major biological age-related changes in older, frail mice that were the equivalent of being 75 human years old. The hormone oxytocin, which is known to suppress tissue repair and decline naturally over time, was paired with an Alk5 inhibitor that blocks the TGF-beta pathway. This was done because TGF-beta activity increases in older tissues and is linked to inflammation and cellular damage.
The male mice that received regular OT+A5i treatment were found to live over 70% longer than mice that were untreated. The treated mice also showed marked improvements in memory, agility, and endurance. Additionally, hazard ratio analysis indicated that the treated male mice were close to three times less likely to die at any moment compared to their untreated counterparts.
“Treatment of old frail male mice with OT+A5i resulted in a remarkable 73% life extension from that time, and a 14% increase in the overall median lifespan.”
Differences in Long-Term Benefits
OT+A5i treatment appeared to restore a more youthful pattern in circulating blood proteins by reducing a recognized indicator of aging called biological noise. While both male and female mice experienced short-term improvements, only the male mice experienced and maintained long-term gains in their systemic protein balance after four months of continuous treatments.
The treated female mice did not display any major improvements in their lifespan or sustained health measures. However, the treated middle-aged female mice did experience increased fertility.
The researchers suggest that these outcomes demonstrate how strongly sex-specific biology can have an influence on the effectiveness of aging and lifespan interventions. While the exact reasons behind the differences are unclear, the study establishes a useful model for understanding how anti-aging therapies may work differently across the two sexes.
Potential Path to Human Lifespan Testing
Oxytocin has already gained FDA approval, and Alk5 inhibitors are currently being evaluated in clinical trials. This means that there is a possibility that this drug combination therapy could one day be adopted for human trials. Given the robust improvements seen in the frail older male mice, the OT+A5i combination therapy might hold promise for enhancing later in life health and survival extension in future clinical trials investigating health and lifespan extension.
As with anything you read on the internet, this article on extending lifespan should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. WHN neither agrees nor disagrees with any of the materials posted above. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement. Additionally, it is not intended to malign any religion, ethnic group, club, organization, company, individual, or anyone or anything. These statements above have not been evaluated by the Food and Drug Administration.
